相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021
Mohd Imran et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2022)
Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents
Mohd Imran et al.
NUTRIENTS (2022)
The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature
Mohd Imran et al.
ANTIOXIDANTS (2022)
An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis
Mohd Imran et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Mohd. Imran et al.
PHARMACEUTICALS (2021)
Synthetic molecules as DprE1 inhibitors: A patent review
Mohd Imran et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
Mohd Imran et al.
BIOMEDICINES (2021)
Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis
Mohit D. Umare et al.
CHEMMEDCHEM (2021)
Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport
Chih-Chia Su et al.
PLOS BIOLOGY (2021)
Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate
Satish R. Malwal et al.
ACS INFECTIOUS DISEASES (2021)
The pipeline of new molecules and regimens against drug-resistant tuberculosis
Todd A. Black et al.
JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES (2021)
An overview of new antitubercular drugs, drug candidates, and their targets
Aparna Bahuguna et al.
MEDICINAL RESEARCH REVIEWS (2020)
Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
Riccardo Miggiano et al.
PATHOGENS (2020)
Targeting MmpL3 for anti-tuberculosis drug development
Jani R. Bolla
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
MmpL3 inhibitors as antituberculosis drugs
Min Shao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets
Rishita Dey et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections
Jigar P. Sethiya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Mycobacterial tuberculosis Enzyme Targets and their Inhibitors
Anil Kumar Saxena et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine
Chih-Chia Su et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
Andre Campanico et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iram Khan Iqbal et al.
PATHOGENS (2018)
Laboratory Diagnosis of Tuberculosis: Advances in Technology and Drug Susceptibility Testing
Seema Oommen et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2017)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
MmpL3 is the flippase for mycolic acids in mycobacteria
Zhujun Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The Challenge of Latent TB Infection
Henry M. Blumberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives
Adrian Rendon et al.
JOURNAL OF THORACIC DISEASE (2016)
Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis
Juan Manuel Belardinelli et al.
ACS INFECTIOUS DISEASES (2016)
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
Norbert Heinrich et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments
Xavier A. Kayigire et al.
TUBERCULOSIS (2015)
MmpL3 a potential new target for development of novel anti-tuberculosis drugs
Geetha Vani Rayasam
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Tuberculosis Vaccines and Prevention of Infection
Thomas R. Hawn et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2014)
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
Katherine A. Sacksteder et al.
FUTURE MICROBIOLOGY (2012)
Giving TB wheels: Public transportation as a risk factor for tuberculosis transmission
Marsha L. Feske et al.
TUBERCULOSIS (2011)
New drugs and regimens for treatment of TB
Eric Leibert et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines
M Protopopova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis
BJ Marais et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2005)
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates
RE Lee et al.
JOURNAL OF COMBINATORIAL CHEMISTRY (2003)
分享论文
